Schlaich MP, Bellet M, Weber MA, Danaietash P, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022 Nov 4. pii: S0140-6736(22)02034.
PMID: 36356632